A5021225962- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Ear and Head Tumors
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Hypoxia, and Metabolism
- Neuroendocrine Tumor Research Advances
- Renal and related cancers
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Phosphodiesterase function and regulation
- Heart Failure Treatment and Management
- Cardiac Fibrosis and Remodeling
- Cancer, Lipids, and Metabolism
- Biosimilars and Bioanalytical Methods
- Gastrointestinal motility and disorders
- Chemotherapy-induced organ toxicity mitigation
- Lung Cancer Research Studies
- Safe Handling of Antineoplastic Drugs
- Neuroblastoma Research and Treatments
- Pathogenesis and Treatment of Hiccups
Sapienza University of Rome
2023-2024
Institute of Cell Biology and Neurobiology
2023
Ospedale Antonio Cardarelli
2008-2020
Fatebenefratelli Hospital
1984-2015
Casa Sollievo della Sofferenza
2009
Beiersdorf (Germany)
2001
Tumour Institute of Tuscany
2000
University of Naples Federico II
1999
Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information available on the predictive role of liquid patients treated with first-line anti-EGFR monoclonal antibody-based therapy.In CAPRI-GOIM trial, 340 KRAS exon-2 wild-type mCRC received cetuximab plus FOLFIRI. Tumor samples were retrospectively assessed by next generation sequencing (NGS). Baseline plasma analyzed and NRAS mutations using beads, emulsion, amplification,...
Abstract Phosphodiesterase 2A (Pde2A) is a dual-specific PDE that breaks down both cAMP and cGMP cyclic nucleotides. We recently highlighted direct relationship between Pde2A impairment, consequent increase of cAMP, the appearance mouse congenital heart defects (CHDs). Here we aimed to characterize pathways involved in development CHDs their prevention by pharmacological approaches targeting signaling. Transcriptome analysis revealed modulation more than 500 genes affecting biological...
BackgroundIn the cetuximab after progression in KRAS wild-type colorectal cancer patients (CAPRI) trial with metastatic (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) first line followed by 5-Fluorouracil, acid, oxaliplatin (FOLFOX) or without until progression. Limited data are available on efficacy safety of anti-epidermal growth factor receptor (anti-EGFR) agents elderly mCRC. In current study we evaluated FOLFIRI plus age-defined subgroups.MethodsA post-hoc...
A specific and sensitive method based on gas chromatography/tandem mass spectrometry with on-column injection was developed to quantify simultaneously cyclophosphamide ifosphamide in urine by using trophosphamide as an internal standard. The samples were extracted diethyl ether derivatization performed heptafluorobutyric anhydride. detection limits of 0.1 0.5 ng ml−1, respectively, a signal-to-noise ratio 3 : 1. sensitivity, the specificity low cost instrumentation involved make this...
The tolerance and antitumor activity of Lonidamine administered alone in combination with other anticancer agents were studied. Myalgia was the most frequent side effect; there no changes hematological parameters attributable to administration. 1 partial response out 16 patients treated observed.
e15066 Introduction: FOLFOX regimen represents a standard first-line therapy for ACRC pts. Oral capecitabine (XEL) has been shown to be convenient and well tolerated alternative intravenous 5-fluorouracil (5-FU) in the treatment of ACRC. Experimental data demonstrated synergism XEL with Oxaliplatin (OHP), but questions about most appropriate dosage schedule have not yet completely resolved. Taking into account these GOIM started phase II study evaluate activity toxicity biweekly...
Metastatic RCC with 38,000 new cases diagnosed in the United States every year is notoriously resistant to conventional chemotherapy and almost invariably an incurable condition. New biologic drugs are beginning break this resistance, reflecting registration of four innovative agents for treatment advanced last 2 years, bevacizumab, sorafenib, sunitinib temsirolimus. Small-molecule multikinase inhibitors targeting VEGF receptors (sunitinib sorafenib) can prolong time progression preserve...
e19630 Background: Chemotherapy-induced anemia has debilitating effects on patients with cancer. Treating associated chemotherapy and many cancers is often necessary. Epoetin therapy a slightly frequency of thromboembolic event (TEE). We investigated the safety profile this treatment in clinical practice, patient compliance, possible correlation between psychological distress frequently present these patients. Methods: Overall, 1552 cancer erythropoietin beta for were enrolled observational...
ABSTRACT Background Phosphodiesterases (PDEs) are the enzymes that hydrolyze cyclic nucleotides (cAMP and cGMP) playing a key role in homeostasis of these two second messengers. PDE2A is dual-specific PDE breaks down both cAMP cGMP can be activated by cGMP. It appears peculiar Pde2A-deficient ( Pde2A -/- ) mouse model embryonically lethal, likely due to strongly reduced size liver severe anemia. In addition, heart embryos shows ventricular atrial septum defects, hypertrabeculation,...